For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and improve lives. It demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the premier research-intensive biopharmaceutical company in the world.
Financial Statements
- Click here to download Merck & Co Inc's Income Statement
- Click here to download Merck & Co Inc's Balance Sheet
- Click here to download Merck & Co Inc's Statement of Cash Flows
Key Info
- Industry: Pharmaceutical Preparation Manufacturing
- Sector: Manufacturing
- CEO Name: Kenneth Frazier
Key Statistics
- Stock Price: $76.58
- Dividend Yield: 3.4000000000000004%
- Market Capitalization: $192,780,041,196
- Shares Outstanding: 2,525,943,936
- Number of Employees: 73,500
- Trailing 12-Month EPS: $2.77
- Trailing 12-Month DPS: $2.6
- Payout Ratio: 93.89999999999999%
Important Dates
- Next Earnings Date: 2022-04-28
- Next Ex-Dividend Date: 2021-12-14
Price Trends
- Current Stock Price: $76.58
- 52-week high: $90.54
- 52-week low: $14.91
- 200-day moving average: $77.75
- 50-day moving average: $78.89
Performance
- 1-Month Price Return: -5.3%
- 3-Month Price Return: -2.7%
- 6-Month Price Return: 1.9%
- 1-Year Price Return: 8.9%
- 2-Year Price Return: 4.5%
- 5-Year Price Return: 35.2%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast